Clinical success with imiquimod alone and in combination with intralesional interferon in basal cell carcinoma


SARICAOĞLU H. , Algan S. I. , Turan A., BÜLBÜL BAŞKAN E. , Turan H., Adim S. B.

TURKDERM-ARCHIVES OF THE TURKISH DERMATOLOGY AND VENEROLOGY, vol.47, no.4, pp.239-242, 2013 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 4
  • Publication Date: 2013
  • Doi Number: 10.4274/turkderm.88319
  • Title of Journal : TURKDERM-ARCHIVES OF THE TURKISH DERMATOLOGY AND VENEROLOGY
  • Page Numbers: pp.239-242

Abstract

Basal cell carcinoma (BCC) is the most common type of skin cancer in humans. Surgery is still the gold standard for treating BCCs. However, there are also less-invasive, nonsurgical therapies such as imiquimod cream and intralesional interferon (IFN) alpha-2b for patients who are poor surgical candidates and who care about cosmetic outcomes. We report 11 patients with various subtypes of. BCC successfully treated with either imiquimod alone or in combination with interferon alfa-2b. In this paper, we present 11 patients with various subtypes of histopathologically proven BCCs, who were treated with imiquimod or combination of imiquimod and IFN alpha-2b, in our outpatient clinic between 2005 and 2010. Of 11 patients, only 4 patients (3 infiltrative, 1 solid types) had received intralesional interferon alpha-2b at a dose of 3 million IU, 3 times a week combined with topical imiquimod while 7 patients had received only 5% imiquimod cream. All patients were cured with these regimens. Imiquimod is found to be effective not only in superficial, but also in infiltrative, solid, and nodular types. Intralesional interferon alpha-2b is also known to be effective in BCCs and it has a synergistic effect when combined with imiquimod.